RA

RAND Launches Building Design Group, Offering Comprehensive Services for Complex Projects

Retrieved on: 
Wednesday, November 1, 2023
MEP, Domestic violence, Hudson River, Local Law 97 of 2019, Engineering, CEM, Heart, CBCP, Floating Hospital, Local, Carbon, Engineer, Architect, DPC, RA, Tenant, AIA, Health education, PE, Mechanical, Tuck, Electricity, High Line, Construction, Retail, Plumbing

NEW YORK, Nov. 1, 2023 /PRNewswire-PRWeb/ -- RAND Engineering & Architecture, a New York City-based firm, is proud to announce the launch of its Building Design Group, a specialized team of experts dedicated to providing comprehensive solutions for complex projects, including adaptive reuse, multi-disciplinary endeavors, gut renovations, and new construction. Led by Principal Peter Varsalona, PE, CEM, CBCP, who brings over 30 years of experience to the team, and Director of Design & Project Management Suzanna Takayama, RA, RAND's Building Design Group offers a multi-faceted blend of architectural design, structural engineering, MEP systems integration, sustainability solutions, forensic engineering, and project management.

Key Points: 
  • RAND Engineering & Architecture, DPC announces the launch of its Building Design Group, a specialized team of experts dedicated to providing comprehensive solutions for complex projects, including adaptive reuse, multi-disciplinary endeavors, gut renovations, and new construction.
  • NEW YORK, Nov. 1, 2023 /PRNewswire-PRWeb/ -- RAND Engineering & Architecture, a New York City-based firm, is proud to announce the launch of its Building Design Group, a specialized team of experts dedicated to providing comprehensive solutions for complex projects, including adaptive reuse, multi-disciplinary endeavors, gut renovations, and new construction.
  • The Building Design Group offers a wide array of services with a particular emphasis on adaptive reuse and multi-disciplinary projects.
  • RAND's services encompassed architectural design, interior design, structural engineering, MEP (Mechanical, Electrical, Plumbing) systems, Special Inspections, and Code and Zoning Compliance.

Organon Canada Announces Availability of a High-Concentration, Citrate-Free Formulation of HADLIMA®, a Biosimilar to HUMIRA*

Retrieved on: 
Thursday, October 26, 2023
Inflammatory Bowel Diseases, Psoriasis, Adolescence, NYSE, Health, Physician, Health Canada, McGill University Health Centre, Rheumatoid arthritis, RA, Ulcerative colitis, McGill University, Crohn's disease, Adalimumab, OGN, Hidradenitis suppurativa, MUHC, Ankylosing spondylitis, Patient, Psoriatic arthritis, Pharmaceutical industry, Organon, Medicine, QC

The availability of both low and high concentration citrate-free options will help enhance patient care for Canadians through more treatment options, while reinforcing Organon's commitment towards biosimilars

Key Points: 
  • The availability of both low and high concentration citrate-free options will help enhance patient care for Canadians through more treatment options, while reinforcing Organon's commitment towards biosimilars
    KIRKLAND, QC, Oct. 26, 2023 /CNW/ - Organon Canada, a subsidiary of Organon (NYSE: OGN), a global healthcare company with a focus on women's health, today announced the availability of HADLIMA® (adalimumab), a biosimilar for Humira* (adalimumab), in a high-concentration, citrate free (40 mg/0.4 mL) version.
  • With this launch, the company reinforces its commitment of offering patients more treatment options and reducing healthcare costs by increasing access to biosimilars.
  • HADLIMA® was previously approved by Health Canada as a low-concentration formulation (40 mg/0.8 mL) in May 2018 and subsequently in a high-concentration (40 mg/0.4 mL) in December 2022.2
    "The launch of citrate-free high concentration HADLIMA® is important for biosimilars in Canada and for Canadians gaining expanded access to treatment options," said Michael Casia, President and Managing Director, Organon Canada.
  • "Organon Canada is committed to the continued expansion of its biosimilar portfolio, helping to strengthen our healthcare system and support patients in need."

Aiolos Bio Launches with $245 Million Series A Investment to Advance Development of Novel, Phase 2-Ready TSLP Antibody

Retrieved on: 
Tuesday, October 24, 2023
Science, Other Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Other Health, CSU, FDA, Hives, Atlas Venture, Bio, Roflumilast, Injection, Rheumatoid arthritis, IPF, Gilead Sciences, RA, Drug development, Senior, Pharmacokinetics, Gilead, Caregiver, Partnership, Asthma, Roche, Genentech, Safety, Therapy, Immunology, Patient, Atlas, COPD, TSLP, Pharmaceutical industry, Aeolus

Aiolos launches with an oversubscribed $245 million Series A investment co-led by Atlas Venture, Bain Capital Life Sciences, Forbion, and Sofinnova Investments with additional investment from RA Capital Management (collectively the “Investor Group”).

Key Points: 
  • Aiolos launches with an oversubscribed $245 million Series A investment co-led by Atlas Venture, Bain Capital Life Sciences, Forbion, and Sofinnova Investments with additional investment from RA Capital Management (collectively the “Investor Group”).
  • The Company will advance its lead drug candidate, AIO-001, into a Phase 2 clinical trial in moderate-to-severe asthma patients and is actively evaluating additional development opportunities.
  • AIO-001 is an anti-thymic stromal lymphopoietin (TSLP) monoclonal antibody that has the potential to be administered only twice per year due to its differentiated potency and long half-life.
  • Aiolos Bio acquired exclusive rights for global development and commercialization of the drug outside of greater China from Jiangsu Hengrui Pharmaceuticals Co., Ltd (“Hengrui”) in August 2023.

Renesas Announces New Organizational Structure to Accelerate Next Phase of Growth

Retrieved on: 
Thursday, October 19, 2023
Technology, Semiconductor, Internet of things, Signal, Enterprise Electronics Corporation, High performance organization, Sales, Digitalization, MCU, Organization, Acquisition, International Union of Operating Engineers, RA, Software, Senior, Intersil, Applied Materials, Growth, Quality assurance, Intel, TSE, Supercomputer, Head, Retirement, Synopsys, Renesas Electronics, Information technology, Global Sales Law Project, Marketing, Nitta, Nevada-California-Oregon Railway Co. General Office Building, Management, Engineering, Power, Analog

Renesas Electronics Corporation (TSE: 6723), a premier supplier of advanced semiconductor solutions, today announced a new organizational structure and leadership team appointments.

Key Points: 
  • Renesas Electronics Corporation (TSE: 6723), a premier supplier of advanced semiconductor solutions, today announced a new organizational structure and leadership team appointments.
  • Chris will be responsible for overseeing Renesas’ power management and discrete products and executing the company’s power strategies.
  • Renesas is creating a centralized engineering organization to solidify Renesas’ engineering foundation, from product to test engineering.
  • Hiroto Nitta, Roger Wendelken and Andrew Cowell will assist with the transition and leave Renesas by the end of the year.

GREENSHIELD ADMINISTRATION RELEASES 2023 DRUG TRENDS REPORT: THE INTRODUCTION OF NEW THERAPIES INCREASE UTILIZATION RATES

Retrieved on: 
Thursday, October 19, 2023
Patient, Lisdexamfetamine, Colitis, Psoriasis, Galcanezumab, Health, Therapy, Social skills, Prevalence, Elijah Cummings Lower Drug Costs Now Act, Migraine, Methylphenidate, Rheumatoid arthritis, RA, Fremanezumab, Crohn's disease, Growth, Disease, Asthma, Pharmacy, Diabetes, Eye, Case management, Calcitonin gene-related peptide, COPD, ADHD, Appetite, Mental health, Pharmaceutical industry, Dietary supplement, Health insurance, Iain Greenshields, Semaglutide

Today, GreenShield introduces its 2023 GreenShield Administration Drug Trends Report , revealing key insights surrounding three main therapeutic categories that go beyond Ozempic.

Key Points: 
  • Today, GreenShield introduces its 2023 GreenShield Administration Drug Trends Report , revealing key insights surrounding three main therapeutic categories that go beyond Ozempic.
  • "In the ever-changing world of healthcare, GreenShield's 2023 Administration Drug Trends Report reveals a compelling narrative, with an overall rise in utilization rates - driven by new therapies and changes in how plan members approach their health," said Mark Rolnick, Executive Vice President, Head of GreenShield Administration.
  • This year's report provides data based on +32 million claims from over two million drug claimants processed by GreenShield Administration this year.
  • Beyond its annual Drug Trends report, GreenShield Administration unlocks better health for all through integrated health and benefits solutions for more than 6 million Canadians from coast-to-coast.

GREENSHIELD ADMINISTRATION RELEASES 2023 DRUG TRENDS REPORT: THE INTRODUCTION OF NEW THERAPIES INCREASE UTILIZATION RATES

Retrieved on: 
Thursday, October 19, 2023
Patient, Lisdexamfetamine, Colitis, Psoriasis, Health, Therapy, Social skills, Prevalence, Elijah Cummings Lower Drug Costs Now Act, Migraine, Methylphenidate, Rheumatoid arthritis, RA, Crohn's disease, Growth, Disease, Asthma, Pharmacy, Diabetes, Eye, Case management, Calcitonin gene-related peptide, COPD, ADHD, Appetite, Mental health, Pharmaceutical industry, Dietary supplement, Health insurance, Iain Greenshields, Semaglutide

Today, GreenShield introduces its 2023 GreenShield Administration Drug Trends Report , revealing key insights surrounding three main therapeutic categories that go beyond Ozempic.

Key Points: 
  • Today, GreenShield introduces its 2023 GreenShield Administration Drug Trends Report , revealing key insights surrounding three main therapeutic categories that go beyond Ozempic.
  • "In the ever-changing world of healthcare, GreenShield's 2023 Administration Drug Trends Report reveals a compelling narrative, with an overall rise in utilization rates - driven by new therapies and changes in how plan members approach their health," said Mark Rolnick, Executive Vice President, Head of GreenShield Administration.
  • This year's report provides data based on +32 million claims from over two million drug claimants processed by GreenShield Administration this year.
  • Beyond its annual Drug Trends report, GreenShield Administration unlocks better health for all through integrated health and benefits solutions for more than 6 million Canadians from coast-to-coast.

Ventricle Health secures $8M in seed financing led by RA Capital Management, along with Waterline Ventures and others to accelerate national delivery of its value-based home care model for heart failure patients

Retrieved on: 
Tuesday, October 17, 2023
RA, Waterline, Cardiology, Heart failure, Kidney, Ageing, Acos, Accountable care organization, GDMT, Kidney disease, Patient, Quality of life, Pharmaceutical industry, Medical device

This investment round will finance the expansion of Ventricle Health’s heart failure management therapeutic model in collaboration with value-based care provider groups and payers.

Key Points: 
  • This investment round will finance the expansion of Ventricle Health’s heart failure management therapeutic model in collaboration with value-based care provider groups and payers.
  • They provide patients access to cardiology care appointments from their home in as little as three days.
  • Ventricle Health’s home-based and virtually enabled care model can reduce the overall average annual cost of heart failure care by at least 30-50%.
  • Employer health costs are similarly rising related to increasing heart failure diagnoses in their aging employee populations.

Silo Pharma’s SPU-21 Peptide Shows Positive Results Against Rheumatoid Arthritis

Retrieved on: 
Monday, October 16, 2023
RA, MS, Tendon, B cell, Central nervous system, Therapy, University, Joint, UMB, Rheumatoid arthritis, SILO, Multiple sclerosis, DSM-IV codes, CNS, University of Maryland, College Park, Medical imaging, Fine chemical

ENGLEWOOD CLIFFS, NJ, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced positive data from a preclinical study investigating the binding affinity and optimization of SPU-21 liposomal joint homing peptide in human synovial tissue surrounding joints and tendons. SPU-21 selectively targets inflamed synovial tissue to inhibit the progression of rheumatoid arthritis (RA).

Key Points: 
  • SPU-21 selectively targets inflamed synovial tissue to inhibit the progression of rheumatoid arthritis (RA).
  • “The purpose of this study was to expand our investigation of our patented SPU-21 cyclic peptide beyond preclinical animal models to human tissue assays,” said Eric Weisblum, Chief Executive Officer of Silo Pharma.
  • “The data shows strong binding affinity to the main stromal cells in human RA synovial tissue, indicating the peptides’ preferential interaction with the inflamed synovial tissue for disease-suppressive effects.
  • In addition to SPU-21, Silo Pharma holds a license agreement with UMB for a central nervous system (CNS) homing peptide targeting multiple sclerosis (MS) and other rare neurological diseases designated.

Carmot Therapeutics Highlights Clinical Data from its Pipeline of Treatments for Obesity and Diabetes at ObesityWeek®

Retrieved on: 
Sunday, October 15, 2023
Type 2 diabetes, RA, Insulin, Pharmacokinetics, Doctor of Philosophy, Obesity, Insulin resistance, T2D, Weight loss, Central nervous system, MD, Physician, Risk, Therapy, OGTT, Diabetes, GIP, Safety, MOA, Overweight, Glucose, DSM-IV codes, Patient, Poster, Pharmaceutical industry, Medical device, Medical imaging, Philosopher's stone

DALLAS, Oct. 15, 2023 (GLOBE NEWSWIRE) -- Carmot Therapeutics Inc. (Carmot), a clinical-stage biotechnology company dedicated to developing life-changing therapeutics for people with metabolic diseases, today announced positive results from the following studies: a study of CT-388 to evaluate the safety/tolerability, efficacy, and pharmacokinetics of CT-388 in people with overweight/obesity without type 2 diabetes (T2D), a study of CT-868 assessing the efficacy and safety of CT-868 in overweight/obese patients with T2D, and a preclinical mechanism of action (MOA) study to investigate the impact of a unimolecular dual biased GLP-1/GIP receptor agonist (RA) in regulating weight loss and food intake. The results are summarized in three poster presentations taking place at ObesityWeek® October 14-17, 2023.

Key Points: 
  • An oral glucose tolerance test was performed on Day -1 (baseline) and Day 23 (post the 4th dose).
  • CT-388 dosed at 5/8/12/12 mg produced 8.4% weight loss (~17 lbs) accompanied by a decrease in waist and hip circumference.
  • Overall, these data support further clinical evaluation of CT-388, with higher doses while maintaining and exploring simpler titration schemes, for the treatment of obesity, T2D and other weight-related comorbidities.
  • Carmot has designed the ongoing Phase 1/2 CT-388 clinical trial to evaluate a higher starting dose, a higher maximum dose and simpler titration schemes.

Carmot Therapeutics Announces that Preliminary Phase 1 Results Support Once-daily Oral Dosing for its Obesity and Type 2 Diabetes Candidate CT-996

Retrieved on: 
Tuesday, October 10, 2023
Type 2 diabetes, RA, Doctor of Philosophy, Obesity, T2D, Weight loss, MD, Physician, Therapy, Diabetes, Overweight, SAD, Clinical trial, DSM-IV codes, Pharmaceutical industry, Vaccine, Philosopher's stone

Preliminary Phase 1 pharmacokinetic (PK) results support once-daily (QD) oral dosing of CT-996.

Key Points: 
  • Preliminary Phase 1 pharmacokinetic (PK) results support once-daily (QD) oral dosing of CT-996.
  • Tolerability results have been consistent with the GLP-1 RA class with the majority of the adverse events being gastrointestinal-related and mostly mild in severity.
  • “We are very pleased to see these preliminary results following single dose administration of CT-996,” said Manu Chakravarthy, MD, PhD, Carmot’s Chief Scientific & Medical Officer.
  • “We believe that the potential to offer a convenient, once-daily oral GLP-1 RA intervention as an alternative to an injection to treat obesity and its comorbidities, such as type 2 diabetes, could be transformative.